SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (OTC: MEHCQ), a genetics-led consumer healthcare company, today announced that it has received approval from the U.S. Bankruptcy Court for the Eastern District of Missouri (the "Court") for the sale of substantially all of the Company's assets and ongoing business operations to TTAM Research Institute ("TTAM"), a nonprofit public benefit corporation based in California and led by 23andMe Co-Founder and former C ...

February 2025 Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the future performance of 23andMe's businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorpor ...

文章核心观点 23andMe宣布与TTAM达成出售资产的最终协议，交易价格3.05亿美元，TTAM承诺遵守隐私政策并加强消费者保护，交易待法院批准 [2][4][7] 交易详情 - 23andMe与TTAM达成协议，出售包括个人基因组服务、研究服务业务线和Lemonaid Health业务在内的几乎所有资产，价格3.05亿美元 [2] - 该协议是今日TTAM与再生元制药最终一轮竞标结果，TTAM为中标者，再生元制药为备用竞标者 [3] - 若法院批准，此协议将取代此前与再生元制药2.56亿美元收购协议 [5] TTAM承诺 - 遵守公司隐私政策和适用法律，按现有同意书、隐私政策等处理客户数据，设安全控制措施保护数据 [4] - 采取额外消费者保护和隐私保障措施，包括尊重客户数据权利、通知客户、限制数据转移、设立隐私咨询委员会等七项内容 [5][6] 各方表态 - 23andMe董事会主席表示竞标使利益相关者获更多价值，增强客户隐私保护， Wojcicki能推进公司愿景 [6][7] - Wojcicki称TTAM将延续23andMe使命，让个人对基因数据有选择权和透明度 [7] 交易进程 - 交易需获破产法院批准和满足惯例成交条件，法院听证会定于2025年6月17日，预计未来几周完成交易 [7] 公司信息 - 23andMe是领先人类遗传学和生物技术公司 [2] - TTAM是加州非营利公益公司，由23andMe联合创始人兼前CEO Anne Wojcicki领导 [2] 顾问信息 - 23andMe法律顾问为Paul, Weiss等，重组顾问为Alvarez & Marsal，投资银行为Moelis & Company，通讯顾问为Reevemark和Scale [9] - TTAM法律顾问为Skadden等，财务顾问为TD Cowen [10] 联系方式 - 投资者联系邮箱investors@23andme.com，媒体联系邮箱press@23andme.com [15]